Gabriel P. Haas

Urology

5000 S 5th Ave
Hines, IL 60141

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 42 publications

Enzalutamide Monotherapy for the Treatment of Prostate Cancer with High-Risk Biochemical Recurrence: EMBARK Secondary End Points: Erratum.

Enzalutamide Monotherapy for the Treatment of Prostate Cancer with High-Risk Biochemical Recurrence: EMBARK Secondary End Points: Erratum.

Journal: The Journal of urology

Published: July 09, 2026

Treatment of High-Risk Biochemically Recurrent Prostate Cancer with Enzalutamide in Combination with Leuprolide: Secondary End Points from the EMBARK Trial: Erratum.

Treatment of High-Risk Biochemically Recurrent Prostate Cancer with Enzalutamide in Combination with Leuprolide: Secondary End Points from the EMBARK Trial: Erratum.

Journal: The Journal of urology

Published: July 09, 2026

Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide.

Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 27, 2026

Reply by Authors.

Reply by Authors.

Journal: The Journal of urology

Published: February 06, 2026

Reply by Authors.

Reply by Authors.

Journal: The Journal of urology

Published: February 06, 2026

Treatment of High-Risk Biochemically Recurrent Prostate Cancer With Enzalutamide in Combination With Leuprolide: Secondary End Points From the EMBARK Trial.

Treatment of High-Risk Biochemically Recurrent Prostate Cancer With Enzalutamide in Combination With Leuprolide: Secondary End Points From the EMBARK Trial.

Journal: The Journal of urology

Published: December 09, 2025

Enzalutamide Monotherapy for the Treatment of Prostate Cancer With High-Risk Biochemical Recurrence: EMBARK Secondary End Points.

Enzalutamide Monotherapy for the Treatment of Prostate Cancer With High-Risk Biochemical Recurrence: EMBARK Secondary End Points.

Journal: The Journal of urology

Published: December 05, 2025

Effects of renal impairment on the pharmacokinetics, safety, and tolerability of pudexacianinium (ASP5354) after IV administration: a mechanistic exploration.

Effects of renal impairment on the pharmacokinetics, safety, and tolerability of pudexacianinium (ASP5354) after IV administration: a mechanistic exploration.

Journal: European journal of clinical pharmacology

Published: November 18, 2025

Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer.

Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer.

Journal: The New England journal of medicine

Published: October 22, 2025

Reliability of Likert Scale for Surgeon-Rated Conspicuity of Ureters with Pudexacianinium Chloride (ASP5354).

Reliability of Likert Scale for Surgeon-Rated Conspicuity of Ureters with Pudexacianinium Chloride (ASP5354).

Journal: JSLS : Journal of the Society of Laparoendoscopic Surgeons

Published: July 16, 2025

Enzalutamide treatment of patients with advanced prostate cancer across the disease spectrum: plain language review.

Enzalutamide treatment of patients with advanced prostate cancer across the disease spectrum: plain language review.

Journal: Future oncology (London, England)

Published: June 30, 2025

Enzalutamide and Prostate-Specific Antigen Levels in Metastatic Prostate Cancer: A Secondary Analysis of the ARCHES Randomized Clinical Trial.

Enzalutamide and Prostate-Specific Antigen Levels in Metastatic Prostate Cancer: A Secondary Analysis of the ARCHES Randomized Clinical Trial.

Journal: JAMA network open

Published: May 07, 2025

Showing 1-12 of 42

Last Updated: 09/26/2026